Results 221 to 230 of about 140,561 (343)

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study [PDF]

, 2004
Teh‐Ia Huo, Yi‐Hsiang Huang, J.‐C. Wu, P.-C. Lee, F.‐Y. Chang, Shin‐Da Lee   +5 more
openalex   +1 more source

Outcome of total necrosis of hepatocellular carcinoma after liver transplantation: is it really totally gone?

, 2022
Jiyoung Kim, Suk Kyun Hong, Sola Lee, Su‐Young Hong, Jeong‐Moo Lee, YoungRok Choi, Nam‐Joon Yi, Kwang‐Woong Lee, Kyung‐Suk Suh   +8 more
openalex   +2 more sources

Calcified nest in the liver: Case report of CNSET. [PDF]

Radiol Case Rep
Chigurupati R, Reddy KH, Patel S, Moorthy S, Kulkarni C, Edala KSP.   +5 more
europepmc   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source

The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma [PDF]

, 2015
Xiao Xu, Di Lu, Runzhou Zhuang, Xuyong Wei, Haiyang Xie, Chao Wang, Yang-Bo Zhu, Jianguo Wang, Cheng Zhong, Xuanyu Zhang, Qiang Wei, Zenglei He, Lin Zhou, Shusen Zheng   +13 more
openalex   +1 more source

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

Portal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao, Sheng Cheng, Qiaoling Pan, Jiong Yu, Hongcui Cao   +4 more
wiley   +1 more source

Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy. [PDF]

J Hepatocell Carcinoma
Wang H, Liu E, Wu M, Gao H, Lv B, Chen G, Zeng X.   +6 more
europepmc   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

Correction: Sequential and synergistic delivery of lipiodol and drug-eluting microspheres circumvents incompatibility to enhance targeted chemoembolization. [PDF]

Front Pharmacol
Frontiers Production Office.
europepmc   +1 more source